Plain-English translation of NCT05551104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing two medications — Nifedipine and Labetalol — to see which one works better and is safer for treating high blood pressure after delivery. Both medications are already used for this purpose, but doctors don't have enough direct comparisons to know which is best. You would take one of these medications (not both) and be monitored to see how well it controls your blood pressure.
High blood pressure after childbirth is common and can be serious, but there's limited research directly comparing these two safe treatment options. This trial will help doctors make better decisions about which medication to recommend for postpartum patients.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either Nifedipine or Labetalol by mouth. The study team will start you on a standard dose and may adjust it based on how well your blood pressure responds. You'll need to follow strict discharge instructions and attend close follow-up appointments after delivery so the doctors can monitor your blood pressure and watch for any side effects.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States
Large-scale testing
Sponsor
Loma Linda University
Enrollment target
~500 participants
Started
May 2023
Primary completion
December 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ashra Denise B Tugung, BSc
Loma Linda University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.